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a  b  s  t  r  a  c  t
Low-grade myoﬁbroblastic sarcoma (LGMS) represents an atypical tumor composed of
myoﬁbroblasts with a predilection for the head and neck, especially in the tongue and oral
cavity, with a high tendency to local recurrences and metastases, even after a long period.
LGMS  arising in the maxillary sinus and in the neck are extremely uncommon. To the best of
our  knowledge, only 50 cases of low-grade myoﬁbroblastic sarcoma have been reported. We
report two cases of LGMS of the maxillary sinus and neck, discussing clinical, histological,
inmunohistochemical and therapeutic features.
© 2013 SECOM. Published by Elsevier España, S.L.U. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Sarcoma  mioﬁbroblástico  de  bajo  grado.  Dos  tumores  infrecuentes  en  dos
localizaciones  poco  habituales
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Recidivas.
r  e  s  u  m  e  n
El sarcoma mioﬁbroblástico de bajo grado (SMFBG) representa un tumor atípico, formado por
mioﬁbroblastos, que tiene predilección por cabeza y cuello, en especial la lengua y la cavidad
oral, y se caracteriza por una elevada tendencia a las recidivas locales y a las metástasis,
incluso después de transcurrido un período prolongado. Los SMFBG que se originan en el
seno  maxilar y en el cuello son excepcionales. Hasta lo que conocen los autores, solo se hanpublicado 50 casos de sarcoma mioﬁbroblástico de bajo grado. Describimos 2 casos en los
que  se identiﬁcaron estos tumores, uno en el seno maxilar y el otro en el cuello, y abordamos
sus características clínicas, histológicas, inmunohistoquímicas y terapéuticas.
©  2013 SECOM. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo
ia CCla  licenc∗ Corresponding author.
E-mail address: maxilogomez@gmail.com (G. Gómez-Oliveira).
http://dx.doi.org/10.1016/j.maxilo.2013.04.004
1130-0558/© 2013 SECOM. Published by Elsevier España, S.L.U. Th
(http://creativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).is is an open access article under the CC BY-NC-ND license
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ntroduction
ow-grade myoﬁbroblastic sarcoma (LGMS) represents an
typical tumor composed of myoﬁbroblasts with a predilec-
ion for the head and neck, especially in the tongue and oral
avity.1,2 Myoﬁbroblasts are mesenchymal spindle-shaped
ells present in almost every soft tissue. LGMS usually occurs
n adult patients with a slight male predominance. Chil-
ren are rarely affected.2 Although LGMS has been studied
xtensively, determining and deﬁning its exact role in the
pectrum of proliferative and neoplastic spindle cell lesions
emains problematic.2 Clinically, patients complain of a pain-
ess swelling or an enlarging mass.2 It is a slow growing
eoplasm with a tendency to local recurrences and metas-
ases, even after a long period.3 The differential diagnosis
ncludes both benign and malignant lesions such as nodu-
ar fasciitis, ﬁbromatoses, ﬁbrosarcoma or leiomyosarcoma.2,4
o the best of our knowledge, only 50 cases of low-grade
yoﬁbroblastic sarcoma have been reported. Now, we report 2
atients with LGMS of the maxillary sinus and neck. Clinical,
istological, inmunohistochemical and therapeutic features
re described.
ase  report
ase  1  (Fig.  1)
 75-year-old female Caucasian was referred to our Oral and
axillofacial Department from the Otolaryngology Depart-
ent, for evaluation of a painful mass in the left maxillary
inus. The mass had appeared one month previously. Her per-
onal and familial medical histories were unremarkable and
he had never smoked or abused alcohol.
Oral examination revealed a minimum but very painful
welling of the left vestibular sulcus of the maxilla. The
verlying mucosa appeared normal. No clinical evidence of
ymphadenopathy was observed.
CT-scan revealed a well-deﬁned mass in the left maxillary
inus with bone destruction of the three walls and partial inﬁl-
ration of the orbital ﬂoor.
An incisional biopsy of the lesion was performed. Micro-
copic examination revealed an expansive mesenchymal
umor characterized by a diffuse proliferation of spindle-
ells with rounded nuclei, small nucleolus surrounded by an
ntense lymphocytic inﬁltrate. On the basis of these clinical,
adiological and histological ﬁndings, the patient was diag-
osed with ﬁbromyxoma versus low grade sarcoma.
The patient underwent, under general anesthesia, a total
axillectomy including pterygoid region, orbital ﬂoor and
ygomatic body, preserving the ocular globe, by means of a
eber-Fergusson incision. The defect was then reconstructed
ith two titanium meshes covered with a myofascial temporal
ap.
Deﬁnitive histological examination showed a ﬁrm mass
f white myxoid tissue with a central cystic area, character-
zed by a mesenchymal proliferation of spindle-cells, ﬁgures of
itosis, areas with myxoid and ﬁbrosclerotic changes as well
s areas of necrosis. There was extensive inﬁltration of the fat . 2 0 1 5;3  7(2):108–112 109
tissue and bone, extending into the zygomatic and palatine
tissue.
Immunohistochemistry revealed that most spindle-cells
were stained diffusely for vimentin, smooth muscle actin,
CD10 and cytokeratin and focally for caldesmon. Staining for
other markers, such as desmin, CD34, ALK, EMA  and S-100
protein was not observed. Proliferative index (Ki-67) was mod-
erate.
Given the age of the patient and the presence of tumor
in the surgical margins, postoperative radiotherapy was per-
formed. After 1 year of follow-up, the patient had a distant
metastasis into the left humerus bone that was resected by
the Traumatology Department. On the other hand, the patient
has no facial or cervical pain and swelling.
Case  2  (Fig.  2)
A 74-year-old man  was referred to our Department for evalu-
ation of an oropharyngeal squamous cell carcinoma relapse
after three previous surgical excisions in another Depart-
ment. Physical examination showed a total absence of the
tongue and the presence of an intraoral pectoral ﬂap with
no evidence of oropharyngeal lesions. CT-scan showed a high
density heterogeneous mass in the tongue base measuring
4.1 cm × 2.5 cm that obliterated the left vallecula. The patient
was diagnosed with tumor relapse and underwent a total
laryngectomy.
Histological examination demonstrated a diffuse mes-
enchymal proliferation composed of spindle cells arranged
in fascicles of varying length that inﬁltrates between indi-
vidual muscle ﬁbers. The nuclei were mostly irregular. Most
tumor cells showed moderate atypia and there were many
mitotic ﬁgures (more than 20 in 10 high power ﬁelds) and focal
areas of necrosis. Proliferative index was high (Ki-67 80%).
Immunohistochemical examination showed diffuse staining
for smooth muscle actin with focal staining for caldesmon.
No other stains were taken up, including desmin, cytokeratin,
EMA  and S-100 protein.
6 months after surgery, the patient presented another cer-
vical relapse treated by means of another surgical intervention
and died in the early postoperative period because of a carotid
artery breakage.
Discussion
Low-grade myoﬁbroblastic sarcoma (LGMS) has a predilec-
tion for the head and neck, especially in the tongue and
oral cavity.1,2 Rare cases involving the salivary glands, the
paranasal sinuses and even the mandible have also been
reported.4–6
Despite isolated case reports, myoﬁbrosarcoma was
deﬁned as a distinct entity only recently.7,8 It usually occurs
in adult patients with a slight prevalence in males. Children
are rarely affected.2
The tumor is composed of myoﬁbroblasts. First described
9by Gabbiani et al. in 1971, they are mesenchymal spindle-
shaped cells that share ultrastructural features with both
ﬁbroblasts and smooth muscle cells.2,10 They are present in
connective tissue and contribute to reparative and reactive
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Fig. 1 – A 75-year-old female with a LGMS of the left maxillary sinus: (A) CT-Scan showing the mass into the maxillary
sinus. Note the orbital ﬂoor destruction in coronal and sagittal images; (B) microscopic section showing a mesenchymal
proliferation of spindle cells arranged in fascicles that inﬁltrates between individual muscle ﬁbers (HE 200×); (C)
immunohistochemistry. Positive stained.
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Fig. 2 – LGMS arising in a 74-year-old man  after previous oropharyngeal squamous cell carcinoma relapse: (A) MRI showing
the relapse of the tumor. Note the proximity of the tumor to the larynx; (B) microscopic examination (HE 200×); (C) note high
grade proliferation index Ki-67; (D) immunohistochemistry. Positive stained.
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onditions, such as granulation tissue, hypertrophic scars,
yoﬁbroblastoma2,3 and even appear in the desmoplastic
troma of carcinoma.11
Clinically, LGMS usually behaves as a slow growing low-
rade malignant sarcoma and exhibits a pattern of aggressive
ocal spread with common local recurrences and eventual
etastatic dissemination, only after a prolonged period of
ime.2,3,10
Nevertheless, in most cases, patients complain of a pain-
ess swelling or an enlarging ﬁrm mass with pale and ﬁbrous
ut surfaces; pain or related symptoms are rarely reported,2
lthough in our two cases, both patients complained of severe
ain, even at rest.
We  must also consider the behavior of the tumor, usually
escribed as slow growing but aggressive at the same time. In
ur cases, there were two different behaviors. The ﬁrst patient
ad a very slow growth with a benign behavior but, on the
ontrary, the second patient had a very fast growth with two
elapses in 6 months and ﬁnally died, even with similar histo-
ogical features. This leads us to believe that histology could
ot be correlated with the clinical course of the patients.
Histologically, most cases are characterized by a diffusely
nﬁltrative growth pattern composed of spindle or stellate cells
rranged in fascicles. More  rarely, a prominent collagenous
atrix with focal hyalinization and numerous thin-walled
apillaries or inﬂammatory cells have also been reported.2,12
eoplastic cells usually have contractile elements and synthe-
ize collagen, ﬁbronectin, laminin3 and show nuclear atypia
ith enlarged, hyperchromatic, irregular nuclei and slightly
ncreased proliferative activity. Mitosis can be presented and
ecrosis is rare.12 The lack of signiﬁcant atypia and mitosis in
ur ﬁrst patient, led us to consider a benign diagnosis such as
bromyxoma, as the ﬁrst choice.
Because this tumor shares histological features, such
yoﬁbroblastic differentiation, with other malignant neo-
lasms (i.e. ﬁbrosarcoma), conventional microscopy is gener-
lly insufﬁcient for a deﬁnitive diagnosis, so that immuno-
istochemical analysis, or electron microscopy may also be
equired.2
Immunohistochemically, cells have a variable
mmunophenotype.11 The markers include smooth muscle
ctin (SMA), desmin, muscle actin (HHF35) and calponin. Most
ells are positive for SMA, while fewer than half are positive for
esmin. Although calponin is usually positive, it is considered
 non-speciﬁc marker. Other markers, such as ﬁbronectin,
imentin, CD34 and CD99, may stain in some cases but are
ot speciﬁc.12 In contrast, LGMS does not stain for S-100
rotein, laminin, epithelial markers (cytokeratin, epithelial
embrane antigen), CD21, CD23, CD117, h-caldesmon and
naplastic lymphoma kinase (ALK).2,3,10 Nevertheless, one of
ur cases, stained diffusely for cytokeratin. Does it mean that
GMS could express epithelial markers in some cases, there
re cells that could differentiate into carcinoma, or maybe
here were two synchronous tumors (LGMS and carcinoma)?.
Some authors insist on ultrastructural studies for cat-
gorizing these tumors and report that positive immuno-
istochemical staining for at least one myogenic marker
an be used to conﬁrm a diagnosis of LGMS.2 Others feel
hat one or more  ultrastructural features should not be the
nly criteria used for diagnosis, and both morphology on . 2 0 1 5;3  7(2):108–112 111
hematoxylin–eosin stained sections and immunohistochem-
istry should be used. On the other hand, other authors report
that recognizing myoﬁbroblastic differentiation is difﬁcult
without electron microscopic examination, but agree that
neoplastic cells have poorly developed ultrastructural features
that may not be identiﬁable in all cases.13,14
It has been established that sarcomas with myoﬁ-
broblastic differentiation can be categorized in several
entities. These include low-grade myoﬁbroblastic sarcoma,
inﬂammatory ﬁbrosarcoma and high-grade or pleomorphic
myoﬁbrosarcoma.10 Given the lack of consensus regarding
diagnostic criteria, myoﬁbroblastic sarcomas are probably
more common than currently noted in the literature, and
may include a variety of clinicopathological forms.2 Contro-
versies surrounding the existence of neoplastic myoﬁbroblasts
and the lack of consensus on diagnostic criteria may be
responsible for this issue.3 As both is relatively rare and
has heterogeneous morphologies, LGMS can be mistaken
for other benign or malignant neoplasms12 such as nodular
fasciitis and ﬁbromatoses both of which may display similar
immunophenotypes,10 myoﬁbroblastic tumors, myoﬁbroma,
myoﬁbromatosis, myopericytoma and sarcomas.2
Spindle cell carcinoma has to be considered in the oral
cavity since it is composed of fasciculated spindle-cells that
express SMA but, unlike LGMS, cytokeratin expression and a
dysplasic epithelium may be seen.3
Other tumors to be considered in the differential diagnosis
include monophasic synovial sarcoma, malignant peripheral
nerve sheath tumor and spindle-cell rhabdomyosarcoma.3
Although the treatment has not been clearly deﬁned, an
aggressive surgical resection with wide tumor-free margins,
and occasionally, radiotherapy or chemotherapy, is the pre-
ferred therapeutic option.2,12
Recurrences in the head and neck are late and described
up to 44%, depending on the treatment used.3 So that, 75%
of patients treated with local excision alone relapsed, while
those who underwent a wide surgical excision with or without
radiotherapy was 7%.12 Nevertheless, in our second case, the
patient presented with a very rapid growth of the tumor with
two recurrences in a very short period of time.
Therefore, recognition of myoﬁbroblastic sarcoma and
appropriate management with close follow-up is essential to
prevent late recurrence or metastases.5
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